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Summary In this paper the biochemical properties of the antigens detected by six murine monoclonal
antibodies (MAbs) are described. These MAbs react selectively with the multidrug-resistant small cell lung
cancer (SCLC) cell line, H69AR, compared to its sensitive parent cell line, H69 (Mirski & Cole, 1989). Because
H69AR cells do not overexpress P-glycoprotein, the antigens detected by these MAbs may be markers for
non-P-glycoprotein-mediated mechanisms of resistance. We found that the 36 kDa protein precipitated by
MAb 3.186 is phosphorylated and has a pl of approximately 6.7. The 55 kDa protein precipitated by
MAb 3.50 is also phosphorylated and has a pI of approximately 5.7. Several observations suggest that MAbs
3.80, 3.177 and 3.187 recognise the same 47 kDa molecule and hence only MAb 3.187 was characterised
further. This MAb precipitates an acidic protein which runs as a streak on isoelectric focusing gels. The 25 and
22.5 kDa cell surface proteins precipitated by MAb 2.54 both have a pl of approximately 7.6. Treatment of
immunoprecipitates with glycosidase F indicated that none of the proteins detected by MAbs 2.54, 3.187, 3.50
and 3.186 have large N-linked carbohydrates. The peptide nature of the epitopes detected by MAbs 2.54 and
3.186 was unequivocally demonstrated by precipitation from in vitro translation products of H69AR RNA.
The antigens detected by MAbs 3.50 and 3.187 were not detectable in immunoprecipitates of translation
products but the epitopes are probably peptides because they were destroyed by boiling in sodium dodecyl
sulphate.
When the reaction of the MAbs with a panel of 15 paired drug-sensitive and -resistant cell lines was
examined in a cell enzyme-linked immunosorbent assay, only a few resistance associated reactions were
observed. Most of the reactions were either negative or not resistance-associated. When tested with three
SCLC cell lines, MAb 3.187 reacted in a manner consistent with the relative resistance of the cell lines.
Antigens that had similar electrophoretic mobility to those from H69AR cells were precipitated from extracts
of five human cell lines of various tumour types. These data indicate that the cross-reactivities of the MAbs
are due to antigens shared among the cell lines and not just the expression of common epitopes on different
proteins. Resistance-associated proteins with the biochemical properties of the antigens described in this paper
have not been reported previously and they remain potential markers for the as yet to be determined
mechanisms of drug resistance in SCLC and other human malignancies.
In most patients with small cell lung cancer (SCLC) the
effectiveness of chemotherapy is limited by the development
of multidrug resistance (Niiranen, 1988). Tissue culture
models for this clinical problem include four adriamycin
(ADM)-selected multidrug-resistant SCLC cell lines, H69AR,
H69/LX4, H69/DAU4 and GLC4/ADR (Mirski et al., 1987;
Twentyman et al., 1986; Jensen et al., 1989; Zijlstra et al.,
1987). Two of these cell lines, H69/LX4 (Twentyman et al.,
1986) and H69/DAU4 (Jensen et al., 1989), overexpress P-
glycoprotein (P-gp+) (Reeve et al., 1989), a plasma mem-
brane protein which confers drug resistance by acting as an
energy-dependent drug efflux pump to reduce the intracel-
lular drug concentration (Bradley et al., 1988). However,
P-gp has been detected infrequently in SCLC tumours that
have developed resistance to chemotherapy, suggesting that
other mechanisms of resistance are likely to be more impor-
tant in this disease (Lai et al., 1989). The H69AR (Mirski et
al., 1987) and GLC4/ADR (de Jong et al., 1990) cell lines,
which do not overexpress P-gp (P-gp-), may therefore be
particularly relevant to the study of multidrug resistance in
SCLC. The molecular basis of the drug resistance in the
H69AR cell line is still uncertain but is probably multifac-
torial. It is known, however,- that this cell line differs from
the GLC4/ADR cell line because H69AR cells do not exhibit
a drug accumulation defect (unpublished observation).
We have previously described six monoclonal antibodies
(MAbs) that detect proteins that might be involved in the
mechanism(s) of H69AR cell drug resistance (Mirski & Cole,
1989). One of these antibodies, MAb 2.54, detects a cell
surface epitope but does not affect the ADM sensitivity of
H69AR cells (unpublished observation). It reacts with multi-
ple proteins of 24.5-34.5 kDa on immunoblots and immuno-
precipitates two proteins of 22.5 and 25.5 kDa. Non-cell
surface, 100,000 x g membrane-associated epitopes are
detected by the other five antibodies, MAbs 3.50, 3.80, 3.177,
3.187 and 3.186. MAbs 3.50 and 3.186 immunoprecipitate
antigens of 55 kDa and 36 kDa, respectively, while MAbs
3.80, 3.177 and 3.187 all precipitate a 47 kDa protein. In this
paper we present a further biochemical characterisation of
the antigens with which these MAbs react in H69AR cells; in
addition, we have examined the reaction of the MAbs with a
panel of paired drug-sensitive and -resistant cell lines to
determine whether these antigens are generally associated
with multidrug resistance.
Materials and methods
Cell culture
The SCLC cell lines, H69, H128 and H209 were provided by
Drs A. Gazdar and J. Minna (NIH, Bethesda, MD). The
MAR SCLC cell line was provided by Prof A.M. Neville
(Ludwig Institute, London, UK) (Ibson et al., 1987). The
P-gp- multidrug-resistant variant of H69, H69AR, was ob-
tained by stepwise selection in ADM and has been described
previously (Mirski et al., 1987). These cell lines were cultured
in RPMI 1640 medium supplemented with either 5% foetal
bovine serum (FBS) (GIBCO Laboratories, Burlington, Ont)
or 5% defined/supplemented bovine calf serum (Hyclone
Laboratories, Logan, UT). The H69/DAU4 cell line is a daun-
orubicin-selected multidrug-resistant variant of the human
SCLC cell line H69 (Jensen et al., 1989) provided by Dr P.
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Jensen (Finsen Institute, Copenhagen, Denmark). The H69/
LX4 cell line is an ADM-selected multidrug resistant variant
of the human SCLC cell line H69 (Reeve et al., 1989) pro-
vided by Dr P. Twentyman (MRC, Cambridge, UK). The
2R50 and IR500-0 cell lines are ADM-selected multidrug-
resistant variants of the human squamous lung carcinoma
cell line SW1573 (Keizer et al., 1989). The 2R50 cell line is
P-gp- while the IR500-0 cell line is P-gp+ (Dr F. Baas,
Netherlands Cancer Institute, Amsterdam, personal com-
munication). These cell lines were cultured in Ham's F-10
medium (Sigma Chemical Co., St. Louis, MO) supplemented
with 10% FBS. HeLa-J2 is an ADM-selected P-gp- drug-
resistant variant of the human cervical carcinoma cell line
HeLa-A6, provided by Dr R.M. Baker (Roswell Park Mem-
orial Institute, Buffalo, NY; personal communication). These
cell lines were cultured in alpha-minimal essential medium
(a-MEM) (GIBCO) with 10% FBS. The MCF-7/MITOX cell
line is a mitoxantrone-selected drug-resistant variant of the
human breast cancer cell line, MCF-7, provided by Dr W.S.
Dalton (Arizona Cancer Center, Tucson, AZ) (Taylor &
Dalton, 1989). The 2780/AD cell line is an ADM-selected
multidrug-resistant variant of the human ovarian carcinoma
cell line A2780/9S (Hamilton et al., 1985). The MES-SA/
MX2 cell line is a mitoxantrone-selected P-gp+ multidrug-
resistant variant of the human uterine fibrosarcoma cell line
MES-SA provided by Dr W.G. Harker (University of Utah,
Salt Lake City, UT) (Harker et al., 1990). The HT1080/DR4
cell line is an ADM-selected P-gp- multidrug-resistant var-
iant of the human fibrosarcoma cell line HT1080 (Slovak et
al., 1988). The 8226/R40 cell line is an ADM-selected multi-
drug-resistant variant of the human myeloma cell line 8226
(Dalton et al., 1986). The HL-60/MX2 cell line is a mitoxan-
trone-selected drug-resistant variant of the human leukaemia
cell line HL-60 (Harker et al., 1989). The CEM/VM-l -5 cell
line is a VM-26-selected drug-resistant variant of the human
leukaemia cell line CEM (Danks et al., 1988). The WIDR/R
cell line is a mitoxantrone-selected drug-resistant variant of
the human colon carcinoma cell line WIDR/S (Dalton et al.,
1988). The CHRC5 cell line is a colchicine-selected multidrug-
resistant variant of the Chinese hamster ovary cell line CHO/
AUXB1 (Ling & Thompson, 1974). The murine macrophage-
like cell line J744.2 and its bleomycin-selected multidrug-
resistant variant were provided by Dr S. Horwitz (Albert
Einstein College of Medicine, New York, NY) and main-
tained in Dulbecco's modified Eagle's medium with 10%
FBS and 1 mm non-essential amino acids.
Unless otherwise indicated, drug-resistant cell lines and
their drug-sensitive parental cell lines were obtained directly
from the laboratories of origin and cultured according to the
conditions described in the references cited. All cell lines were
cultured at 37°C in 95% air, 5% CO2 atmosphere and were
free of mycoplasma contamination.
Monoclonal antibodies
The production of MAbs 2.54, 3.50, 3.186, 3.80, 3.177 and
3.187 has been described previously (Mirski & Cole, 1989).
Spleen cells from BALB/c mice which had received multiple
injections of viable H69AR cells, were fused with P3.NS1/
Ag4.1 (NS-1) myeloma cells and hybridomas were selected
which (i) reacted with H69 cells similar to negative control
(NS-1 ascites) values in a cell enzyme-linked immunosorbent
assay (ELISA), (ii) had a ratio of ELISA absorbance values
(H69AR: H69) greater than 5, and (iii) had consistent specific
reactivity with H69AR cells following cloning, expansion and
freezing.
Enzyme-finked immunosorbent assay
Binding of the MAbs to monolayers of tumours cells was
assessed by a modification of the method ofGlassy and Surh
(1985) as described previously (Mirski & Cole, 1989). Briefly,
5 x 104cells per well, in 96 well polyvinyl chloride plates
(Falcon 3912, Becton-Dickinson, Oxnard, CA), were dried
overnight at 37°C and used immediately or stored at 4°C and
used within 1 week. Hybridoma culture supernatant was
added at 1:5 final dilution or ascites at 1:250 final dilution in
a blocking solution of 1% bovine serum albumin (BSA), 5%
normal goat serum (NGS) in phosphate-buffered saline
(PBS). Binding of the MAb was detected using horseradish
peroxidase-conjugated goat anti-mouse Ig(G + M + A) affin-
ity purified F(ab')2 fragments (Cappel, Cooper Biomedical,
Malvern, PA) with o-phenylenediamine and hydrogen perox-
ide as substrates. Colour development was measured on a
Dynatech MR600 microtitre plate reader.
Immunoblotting
Cells were homogenised in 10mM Tris-HCl, pH 7.6 buffer
containing 10 mM KCl, 1.5 mM MgCl2, 2 mM phenylmethyl-
sulfonyl fluoride (PMSF) and 0.5% Aprotinin (Sigma) at
4°C, and 100,000g membranes were prepared by the method
of Gerlach et al. (1987). Cell membrane preparations in
sample buffer without 2-mercaptoethanol (2-ME) were run
on sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE)
and replica blotted onto Immobolin (Millipore, Mississauga,
Ont) by the method of Towbin et al. (1979). The blot was
blocked with 5% FBS/5% NGS/0.05% Tween 20 in PBS
(blocking buffer) and then incubated with MAb 2.54 or
MAb 3.186 or NS-1 negative control ascites diluted 1:500 in
blocking buffer. Binding of the MAbs was detected using
alkaline phosphatase-conjugated goat anti-mouse IgG (Jack-
son ImmunoResearch Laboratories, West Grove, PA) with
nitroblue tetrazolium and bromochloroindolyl phosphate
(Sigma) as substrates (Mierendorf et al., 1987).
Immunoprecipitations
MAb ascites, rabbit anti-mouse Igs (DAKO Immunoglob-
ulins, Denmark) and S.aureus (Sigma) were used to immuno-
precipitate antigens, as previously described (Mirski & Cole,
1989), from 100,000g membranes or crude extracts prepared
from cells which had been labelled in tissue culture. Alterna-
tively, to reduce non-specific precipitation, protein A Seph-
arose CL-4B (Pharmacia, Balie d'Urfe, Que) was used and
was incubated with rabbit anti-mouse Igs, and MAb ascites
and washed prior to use. Immunoprecipitates were washed,
boiled 5 min in sample buffer with 2-ME, microfuged, and
the supernatant loaded for SDS-PAGE.
Cells were cultured in the presence of 30pCi ml-' 35S
methionine (cell labelling grade, 640-700Cimmol-') (Du-
Pont, Mississauga, Ont) for 24 h in methionine-deficient
RPMI 1640 (Sigma) with 10% dialysed FBS or with 750
fCi ml- 32P04 (8500-9210 Ci mmol-1) (DuPont) in phos-
phate-deficient Minimum Essential Medium, Eagle (modified)
with Earle's salts (Flow Laboratories, McLean, VA) and
10% dialysed FBS for 2.5 h. An aliquot of 100,000g mem-
brane containing approximately 2 x 106 acid-precipitable
c.p.m. of 35S or 4 x 105 acid-precipitable c.p.m. of 32p was
immunoprecipitated.
In some experiments, immunoprecipitates were used for
two dimensional electrophoresis as described by O'Farrell et
al. (1977). The first dimension was isoelectric focusing with
pH 3 to 10 Ampholines (Pharmacia) or non-equilibrium pH
gradient electrophoresis (NEPHGE) in which the pH
gradient is reversed. The second dimension was SDS-PAGE.
Carbamylated protein standards (Pharmacia) were used to
estimate pl. Gels were fixed, those containing 35S were soaked
in Amplify (Amersham, Oakville, Ont) and dried. Autoradio-
graphs were obtained with Kodak X-AR film at - 70°C.
Enzyme digestions
A glycosidase F preparation containing endoglycosidase F
and glycopeptidase F in a 1:1 ratio (Boehringer Mannheim,
Indianapolis, IN) was used to hydrolyse hybrid and complex
oligosaccharides using conditions recommended by the sup-
plier. Briefly, proteins were denatured by boiling for 3 min
with SDS (SDS:protein ratio of 1:1 by weight), and the
sample diluted so that the final concentration of SDS in theMULTIDRUG RESISTANCE-ASSOCIATED ANTIGENS 17
incubation mix was approximately 1 mg ml' in 0.25M Na
acetate, pH 7 with 0.01% NaN3, 6 mgml- NP-40, 20 mM
EDTA, 10 mM 2-ME, 1 mM PMSF, and 0.5% Aprotinin.
Endoglycosidase F was added to a final concentration of 3.4
to 3.6 units ml-', and incubated at 37C for 17 to 19 h.
Negative control digestions were performed in the absence of
enzyme. For some experiments 100,000g membrane prepara-
tions of H69AR cells which had been labelled in culture with
35S methionine were digested with the endoglycosidase
F preparation and then immunoprecipitated with the MAbs.
In other experiments digestions were performed on immuno-
precipitates. Digests of fetuin were included in both types of
experiment and the increase in its electrophoretic mobility
was monitored as a positive control for enzyme activity.
a
Acidic (+)
LA
c
V
IEF Basic (-)
-69
46
- 30
3.50
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Acidic (+) NEPHGE Basic (-)
In vitro translations
Total RNA prepared from H69AR cells by the guanidine-
HCI/sodium acetate method of Deeley et al. (1977) was
translated in vitro in the presence of 0.3 mCi 35S methionine
ml-' (translation grade, 1146 Ci mmol-') (DuPont) using a
rabbit reticulocyte lysate kit (Promega, Madison, WI) and a
final RNA concentration of 200pg ml-'. Immunoprecipitates
from 2.4 x 106 to 6.0 x 106 acid-precipitable c.p.m. of the in
vitro translation products were processed for SDS-PAGE and
autoradiography as described above.
Lu
3.186
c
Acidic (+) NEPHGE Basic (-)
Results
We have previously shown that MAbs 3.187, 3.177, and 3.80
all precipitate proteins of 47 kDa, suggesting that they may
detect epitopes on the same protein (Mirski & Cole, 1989). In
this study, the cell ELISA reaction pattern of each of these
MAbs was the same in all 14 pairs of drug-sensitive and
-resistant tumour cell lines tested (data not shown), providing
additional evidence that these three MAbs likely detect
epitopes on the same molecule. For this reason, MAb 3.187
was selected as a representative of this group for use in most
subsequent experiments.
Two-dimensional gel electrophoresis showed that the anti-
gen precipitated by MAb 3.50 is acidic (approximate pl 5.7)
(Figure la). The antigen precipitated by MAb 3.187 was also
acidic, but a pl could not be determined because the protein
ran as a streak (data not shown). The immunoprecipitates
obtained with MAbs 3.186 and 2.54 were run on NEPHGE
to obtain an estimate of pIs which were approximately 6.7
and 7.6 respectively (Figure lb and lc).
To determine if the proteins detected by the MAbs are
phosphorylated, immunoprecipitations were performed on
membrane preparations from H69AR cells that had been
labelled in culture with 32p04. As shown in Figure 2, the
molecules detected by MAbs 3.50 and 3.186 are phosphory-
lated but phosphorylation of the other antigens were not
detected.
Several approaches were taken to determine if the antigens
detected in H69AR cells are glycosylated and whether the
epitopes detected are peptide or carbohydrate in nature.
First, H69AR membrane preparations were digested with
endoglycosidase F and glycopeptidase F and immunoprecipi-
tated. MAb 3.186 precipitated a protein of the same electro-
phoretic mobility from digested or control H69AR mem-
branes, suggesting that the epitope detected is not an N-
linked carbohydrate and that the antigen is not extensively
glycosylated (results not shown). Results from digestions with
endoglycosidases prior to immunoprecipitation were not in-
formative for MAbs2.54, 3.50 and 3.187 because the epi-
topes were destroyed in the control digests without enzyme.
Control digests required boiling of the cell extract in SDS.
This resulted in the loss of antigenicity detectable by
MAbs 3.50 and 3.187, suggesting that these epitopes are
peptides (Feizi & Childs, 1987). The inclusion of 2-ME
caused the loss of MAb 2.54 antigenicity. In a second ap-
proach, 35S methionine-labelled immunoprecipitates were di-
gested with endoglycosidase F and glycopeptidase F and no
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Figure 1 Two-dimensional gel electrophoresis of immunopre-
cipitates from 100,000g membrane preparations of 35S methio-
nine labelled H69AR cells a, MAb 3.50, b, MAb 3.186 and c,
MAb 2.54. Numbers and arrows below the gel indicate the
specifically immunoprecipitated protein. Arrows and numbers to
the right of the gels indicate the position of molecular weight
markers ( x 1000).
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Figure 2 SDS-PAGE of immunoprecipitates with MAbs 3.50
and 3.186 from 100,000g membrane preparations of 32PO4 la-
belled H69AR cells. Arrows and numbers to the left of the gel
indicate the position and molecular weight ( x 1000) of specifi-
cally precipitated proteins. Arrows and numbers to the right of
the gel indicate position of molecular weight markers ( x 1000).
change in the size of the proteins was seen, suggesting that
large N-linked carbohydrates are not present on these anti-
gens (results not shown). In a third approach, we attempted
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to radiolabel glycoproteins for use in immunoprecipitation
experiments by culturing H69AR cells in glucose-depleted
medium in the presence of 3H-N-Acetyl-D-glucosamine or
3H-glucosamine. However, the radioisotope incorporation
was so low that immunoprecipitates would not have pro-
duced a detectable signal even if the antigens had been
glycosylated. A final approach was to translate RNA pre-
pared from H69AR cells in the presence of 35S methionine,
using a rabbit reticulocyte lysate system which does not
glycosylate proteins. The protein precipitated by MAb 3.186
from the in vitro translation products of H69AR RNA had
the same estimated molecular weight as that precipitated
from H69AR cell extracts (Figure 3). These results provide
conclusive evidence that the epitope detected by MAb 3.186
is a peptide and that the antigen is not heavily glycosylated.
Proteins were not convincingly detectable above high back-
grounds after immunoprecipitation of the translation pro-
ducts of H69AR RNA with MAbs 3.50 or 3.187. MAb 2.54
did not immunoprecipitate proteins directly from the transla-
tion products presumably because the reaction mixture con-
tained 2-ME which destroys the epitope (Mirski & Cole,
1989). In an attempt to renature the protein, the translation
products (in buffer with protease inhibitors) were left open
on the bench overnight to allow the 2-ME to evaporate. This
treatment produced an in vitro translated protein of 20.5 kDa
that was precipitated by MAb 2.54 but was smaller than the
proteins precipitated in the same experiment from H69AR
cell extracts (22.5 kDa and 25 kDa) (Figure 3). Taken to-
gether, these data show that the epitopes recognised by
MAb 3.186 and 2.54 are peptides and provide some evidence
that the epitopes recognised by MAbs 3.50 and 3.187 are
peptides as well.
The characteristics of the four antigens are summarised in
Table I.
To determine if the epitopes detected by the MAbs in
H69AR cells are resistance-associated in other cell lines, the
reaction of MAbs 2.54, 3.50, 3.186 and 3.187 with a panel of
15 paired drug-resistant and parental drug-sensitive tumour
cell lines was examined by cell ELISA (Figure 4). Resistance-
associated reactions were defined as those in which the
relative absorbance on the resistant cell line was at least two
times that of both its parental drug-sensitive cell line and the
H69 cell line. Such reactions were observed with MAb 2.54
on 2780/AD cells and MAb 3.187 on IR 500-0, 2R50 and
MES-SA/MX2 cells. The reactions of the MAbs with the
other human cell lines were either negative or not resistance-
associated. All four non-human cell. lines tested were negative
with MAbs 2.54, 3.186 and 3.187 but had some reactivity
with MAb 3.50.
Immunoblots with MAbs 2.54 and 3.186 (Figure 5) and
immunoprecipitations with MAbs 3.186, 3.50, 3.80, 3.177 and
3.187 (Figure 6) were performed on extracts of several
tumour cell lines to determine if the epitopes detected were
on the same protein as in the H69AR cell line. Faint reac-
tions with proteins of the same molecular weight as in
H69AR cells were observed on immunoblots of 2780/9S cells
with MAb 3.186 and on 2780/AD cells with MAbs 3.186 and
2.54 (results not shown). The weak intensity of the reaction
on immunoblots and the strong signal from 3.50 immunopre-
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Figure 3 SDS-PAGE of immunoprecipitates with MAbs 3.50
and 3.186 from 35S methionine labelled in vitro translation pro-
ducts (t.p.) of H69AR RNA and from I'S methionine labelled
H69AR 100,000g membranes (memb.). Arrows and numbers to
the right of the gel indicate position and weight ( x 1000).
Numbers below the lanes indicate the MAb used for immunopre-
cipitation. Arrows and numbers at left indicate the position and
weight ( x 1000) of specifically precipitated proteins.
cipitates (Figure 6) with the 2780 cell lines was consistent
with the intensity of reactions observed with these MAbs in
the cell ELISA (Figure 4). Without exception, the proteins
detected by the MAbs in the drug-sensitive and drug-resistant
WIDR cell lines (Figures 5, 6d) and the multidrug-resistant
cell lines HT1080/DR4 (Figure 6a), 2780/AD (Figure 6b) and
MES-SA/MX2 (Figure 6c) had similar electrophoretic mo-
bility to those detected in H69AR cells.
The reactions of the MAbs on two SCLC cell lines estab-
lished from untreated patients (H209 and MAR), and two
SCLC cell lines established from treated patients (H128 and
H69), are presented in Figure 7. The relative absorbances for
MAbs 2.54, 3.50 and 3.186 on SCLC cell lines H128, H209
and MAR were similar to those of H69 cells. MAb 3.187
reacted equally with H209, MAR and H69 cells but produced
a relative absorbance with H128 cells that was approximately
twice that of H69 cells.
Discussion
The overexpression of P-gp has rarely been detected in
tumour samples from patients with SCLC (Lai et al., 1989),
suggesting the P-gp- H69AR cell line may be particularly
valuable for studying multidrug resistance in this tumour
type. We have produced six MAbs which react selectively
with the H69AR cell line compared to its drug sensitive
parent, H69 (Mirski & Cole, 1989). These MAbs define
markers associated with the drug resistance phenotype in
H69AR cells and possibly in other cell lines as well.
Table I Biochemical properties of antigens on H69AR cells
Molecular weight (kDa)
memb. memb. i.v.t. Protein
MAb blota precip.b precip.c pI Phosphorylated epitope
2.54 24-34 22.5 + 25 20.5 7.6 ND yes
3.50 NDd 55 ND 5.7 yes probably
3.186 36 36 36 6.7 yes yes
3.187 ND 47 ND acidic ND probably
aMolecularweightswereestimated fromimmunoblotsofH69AR100,000gmembranes
(memb. blot). bMolecular weights were estimated from immunoprecipitates from 35S
methionine labelled H69AR 100,000g membranes (memb. precip.). cMolecular weights
were estimated from immunoprecipitates from 3"Smethionine labelled in vitro translation
products (i.v.t. precip.) of H69AR RNA. dND, not detectable.MULTIDRUG RESISTANCE-ASSOCIATED ANTIGENS 19
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Figure 4 Reaction of MAbs with paired drug-sensitive and -resistant tumour cell lines in a cell ELISA. a, Drug-resistant member
ofpaired sensitive (hatched bars) and resistant (filled bars) cell line is named. The sources of the cell lines are indicated in Materials
and methods. b, Mean of duplicate determinations of absorbance values, expressed relative to absorbance values obtained with
H69AR cells in the same experiment. MDR: multidrug-resistant.
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Figure 5 Immunoblots of extracts from H69AR (AR), WIDR/
R, and WIDR/S, HT1080 and HT1080/DR4 cells with MAbs
2.54 and 3.186. Equal protein was loaded for each member of a
drug-sensitive and -resistant pair of cell lines. Arrows and num-
bers at right and left indicate position and molecular weight
( x 1000) of specifically detected proteins. No proteins were
detected by the negative control NS-1 ascites (not shown).
The antigen detected by MAb 3.186 is a 36 kDa protein
with a pl of 6.7 (Figure lb). It is phosphorylated (Figure 2)
but does not contain detectable N- or 0-linked carbohy-
drates. Multiple proteins of less than 36 kDa are occasionally
detected by MAb 3.186 in H69AR cells and in other cell lines
(Figures 5 and 6). The variability of this observation and the
smaller size of these additional proteins suggests that they
may be proteolytic degradation products of the larger 36 kDa
protein, despite the presence of protease inhibitors in the lysis
buffers. Similarly, we believe that the smaller of the two
proteins precipitated by MAb 2.54 (25 kDa and 22.5 kDa)
may be a degradation product of the larger protein. In
addition we found that the 2.54 antigen (pI approximately
7.6) (Figure 1c) was not detectably phosphorylated or N-
glycosylated.
The 55 kDa protein precipitated by MAb 3.50 is acidic (pl
approximately 5.7) (Figure la) but does not contain detec-
table N-linked carbohydrates. Like the 3.186 antigen, the
antigen precipitated by MAb 3.50 is phosphorylated. This
finding is of interest because the activity of proteins is often
regulated by phosphorylation. For example, phosphorylation
may have a regulatory role in P-gp-mediated multidrug resis-
tance since Hamada et al. (1987) observed increased phos-
phorylation of this protein when cells were exposed to agents
that inhibit active drug efflux. In addition, Chambers et al.
(1990) have shown that phorbol 12-myristate 13-acetate
treatment of cells increased both the phosphorylation of P-gp
and its activity as indicated by decreased drug accumulation.
Further studies are required to determine if the level of
phosphorylation of the 3.50 and 3.186 antigens affects the
drug resistance phenotype of H69AR cells.
Several observations suggest that MAbs 3.80, 3.177 and
3.187 detect epitopes on the same molecule. Firstly, they all
immunoprecipitate 100,000 g membrane-associated proteins
of 47 kDa (Mirski & Cole, 1989). Secondly, these three
MAbs react in identical fashion on 14 pairs of drug sensitive
and resistant tumour cells in a cell ELISA. Finally, all three
MAbs immunoprecipitate proteins of the same size from the
drug-resistant cell lines H69AR, MES-SA/MX2 and HT1080/
DR4 and the drug-sensitive cell line WIDR/S (Figure 6).
Experiments with MAb 3.187, as representative of these three
MAbs, have shown that the protein precipitated is not detec-
tably phosphorylated or N-glycosylated.
The biochemical nature of the epitopes with which the
MAbs react was determined using a number of techniques.
Evidence from digestions with endoglycosidase F and glyco-
peptidase F and from in vitro translations of H69AR RNA
(Figure 3) show that the epitope recognised by MAb 3.186 is
a peptide. Determining whether the epitopes detected by
MAbs 2.54, 3.50 and 3.187 were peptide or carbohydrate was
complicated by their sensitivity to incubation in digestion
buffer alone. However the very fact of their sensitivity to this
treatment, together with the observations that MAb 2.54
reactivity is lost by boiling in sample buffer with 2-ME
(Mirski & Cole, 1989) and MAb3.50 and 3.187 reactivities
are lost by boiling in SDS, suggest that these epitopes are
peptides (Feizi & Childs, 1987). Indeed, the specific immuno-
precipitation by MAb 2.54 of a protein from in vitro transla-
tion products of H69AR RNA (Figure 3) confirms that this
epitope is a peptide. The molecular weight of the 2.54 antigen
precipitated from in vitro translation products (20.5 kDa)
is significantly less than that from H69AR membranes
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Figure 6 SDS-PAGE of immunoprecipitates from extracts of 35S methionine labelled human tumour cell lines. a, HT1080/DR4; b,
2780.AD645; c, MES-SA/MX2; d, WIDR/S. Arrows and numbers at right of each gel indicate position of molecular weight
markers ( x 1000) and arrows at left indicate position and weight ( x 1000) of specifically precipitated proteins. The MAb used for
immunoprecipitation is indicated below each lane. NS-1 ascites was used for negative control immunoprecipitations.
(22.5 kDa and 25 kDa) for reasons that are unclear at the
present time (Figure 3). However, it is worth noting that it
was necessary to allow the 2-ME to evaporate from the in
vitro translation mix before an immunoprecipitate could be
formed by this MAb and proteolysis might have occurred
during this overnight incubation at room temperature. In
general, we have observed a progressive decrease in the size
of the protein detected by MAb 2.54 as the time the antigen
might be exposed to proteases increases, viz., in immuno-
blots, precipitations from membranes and precipitations from
translation products. In further support of this idea, proteins
as small as 20.5 kDa were occasionally detected with
MAb 2.54 on immunoblots (Figure 5). Because the evidence
is unequivocal that epitopes detected by MAbs 2.54 and
3.186 are peptides, these antibodies can be used to screen
cDNA expression libraries.
Despite the evidence that there are no N-linked carbohy-
drates on the antigens and that the epitopes are sensitive to
boiling in SDS, we cannot completely eliminate the pos-
sibility that the epitopes detected by MAbs 3.50 and 3.187
may be carbohydrate because they did not immunopre-
cipitate detectable translation products of H69AR RNA. One
possible explanation for this result is that the epitopes recog-
nised by these MAbs may not be on the unmodified transla-
tion products. The antigens may not assume the appropriate
tertiary configuration for recognition because the translation
system is not capable of signal peptide cleavage, membrane
insertion, or translocation. Alternatively, the 3.50 and 3.187
antigens may not be sufficiently abundant or may contain too
few methionine residues to allow detection since they produce
weak signals, compared to the other antigens, when
precipitated from H69AR membranes.
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Figure 7 Reaction of MAbs with SCLC cell lines in a cell ELISA. The sources of the cell lines are indicated in the Materials and
methods. b, Absorbance expressed relative to absorbance values obtained with H69AR cells in the same experiment. Bars represent
the mean relative absorbance (± s.d.). Determinations were done in duplicate in each experiment and 2 to 5 experiments were
performed per cell line.
Using a panel of paired drug-sensitive and resistant cell
lines, we determined whether the reactions of the MAbs are
generally resistance-associated. The panel included represen-
tatives of three different drug-resistance phenotypes: eight cell
lines that overexpress P-gp, two cell lines that do not overex-
press P-gp and five cell lines that do not overexpress P-gp but
have cross-resistance patterns not typically associated with
the multidrug resistance phenotype (Bradley et al., 1988). The
MAbs did not distinguish among these three groups. Most
reactions were either negative or not resistance-associated
'Figure 4). The ELISA reactions (Figure 4) appear to be due
to common antigens on the various cell lines, and not merely
identical epitopes on different proteins because the proteins
that were precipitated from five cell lines of different tumour
Sypes had similar electrophoretic mobility to those detected in
H69AR cells (Figures 5 and 6).
Strong ELISA reactions on several drug-sensitive cell lines
wvere observed. This does not necessarily indicate that the
intigens are unrelated to the resistance phenotype because
;he so-called drug-sensitive cell lines vary widely in their
^elative sensitivity to drugs. Of the 15 paired cell lines
;creened, only two had a similar phenotype to H69AR (i.e.
WDR', P-gp-). However, the cross-resistance patterns of
hese two cell lines are quite distinct, suggesting that different
nechanisms may be responsible for their resistance. Thus it
*emains possible that these antigens are potential markers for
;pecific mechanisms of drug resistance which may not as yet
iave been identified.
In contrast to our previous study (Mirski & Cole,
1989), no resistance-associated reactivity was observed with
VIAbs 3.186, 3.50 and 3.187 on the P-gp- human fibrosar-
,oma HT1080/DR4 cell line (Figure 4). This experiment has
)een repeated multiple times over a period of 12 months and
)ecause we have consistently found no resistance-associated
eactivity, we have greater confidence in the present data.
rhe basis for the discrepancy is unknown, but does not
tppear to be due to evolution of the drug-sensitive cell line
ince HT1080 cells thawed from an early passage also reacted
vith the MAbs.
Resistance-associated reactions were observed with MAb
!.54 on human ovarian 2780/AD cells and with MAb 3.187
n uterine sarcoma MES-SA/MX2 cells and on the two
elated lung carcinoma cell lines IR 500-0 and 2R50; how-
ver, these reactions were relatively weak compared to those
)n H69AR cells (Figure 4). MAb 3.187 reacted in the ELISA
'(Figure 7) in a manner consistent with the relative sensitivity
of three SCLC cell lines to drugs such as DOX, VP-16, and
vinblastine (Campling et al., 1991). Screening of a larger
panel of SCLC cell lines is underway and clearly such studies
are required before any comments can be made regarding the
significance of this data.
It is interesting to note that the antigens were not overex-
pressed in the resistant P-gp+ H69/LX4 and H69/DAU4 cell
lines (Figure 4) nor in the P-gp- SCLC cell line, GLC4/ADR
(Dr J. Zijlstra, personal communication). These results indi-
cate that the MAbs will not distinguish all multidrug resis-
tant SCLC cells from sensitive cells and are consistent with
the idea that multidrug resistance in this tumour type is
heterogeneous (Bergh et al., 1990). Ultimately, the usefulness
of the antibodies must be determined by screening large
numbers of clinical samples.
In summary, MAbs 2.54, 3.50, 3.186 and 3.187, raised
against the H69AR cell line detect peptide epitopes on four
distinct antigens that are also expressed in some other drug-
sensitive and -resistant cell lines. Proteins with the same
biochemical properties and cellular location have not pre-
viously been associated with multidrug resistance and thus
these proteins are potential novel markers for resistance.
However, since the expression of these antigens was often of
similar intensity on paired drug-sensitive and -resistant lines
and was rarely resistance-associated, they are unlikely to be
widely useful as general drug resistance markers. Never-
theless, the possibility remains that these antigens may be
markers for several resistance mechanisms; the relative im-
portance of each mechanism may differ in the various cell
lines in which drug resistance has a multifactorial basis
(Batist et al., 1986; Zijlstra et al., 1987; Deffie et al., 1988).
The cDNA cloning of the antigens described in this study is
underway and, once their sequence is known, it should be
feasible to synthesise anti-sense oligonucleotides to selectivity
turn off expression of each antigen and thereby determine its
contribution to the multidrug resistance phenotype observed
in the H69AR cell line.
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